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Summary: Four enzymatic methods for creatinine measurement were evaluated on a DuPont Dimension™
automatic analyzer. Biomed Creatinine-Duo-UV (BIO) and Raichem™ Creatinine Reagent Enzymatic (RAI)
start creatinine breakdown with creatinine iminohydrolase (EC 3.5.4.21) resulting in the formation of NH/.
The Boehringer Mannheim Creatinine PAP (BM1) and SopaChem Creatinine (SOP) start the breakdown of
creatinine with creatininase (EC 3.5.2.10) which yields creatine. In order to reduce bilirubin interference, the
BM1 method was modified to contain K4Fe(CN)6. This substance was added with reagent l (BM2) or with
reagent 2 (BM3). All the enzymatic creatinine methods tested displayed good linearity for concentrations up
to at least 1000 μπιοΐ/l. The ΒΙΟ, BM3, RAI and SOP methods showed good stability of test outcome for
the tested period of a week. The outcome of the BM1 and BM2 method increased continually with time.
Only the results of the RAI method were diminished by the presence of lipids. The BM1, BM2, BM3 and
SOP methods showed no interference with haemoglobin, whereas this increased the outcome of the BIO
method and slightly decreased the results of the RAI method. Using spiked human albumin solutions it was
found that the ΒΙΟ, BM2, BM3 and RAI methods displayed good resistance to interference by bilirubin or
ditauro-bilirubin. The outcome of the BM1 and SOP method was strongly decreased by both bilirubin and
ditauro-bilirubin. When creatinine was measured in a panel of sera originating from 100 patients with bilirubin
concentrations higher than 50 μιηοΐ/ΐ, the obtained results were in close agreement with those found for the
spiked human albumin solutions. Considering the conditions evaluated, our conclusion is that the Boehringer
Mannheim Creatinine PAP method adapted to contain K4Fe(CN)6 in reagent 2 (BM3) performs best of the
methods tested on the DuPont Dimension™ automatic analyzer.
kaline conditions as described in 1886 by Jaffe (3).
Creatinine is formed from creatine and creatine phos- Ever since this method was first used to quantify
phate at a rate dire'ctly related to total muscle mass creatinine (4), it has been considered unsatisfactory
and, thus, roughly to body weight. Because creatinine and much effort has gone into circumventing the
is produced at a fairly constant rate and is not re- limitations of this technique (1, 5, 6). Nowadays the
used in the body, the serum concentration is almost Jaffe creatinine test is usually configured to a two-
completely dependent on the creatinine clearance. As point, fixed time, kinetic measurement with or without
creatinine is cleared exclusively by glomerular filtra- correction algorithm (7). In this way the fast reaction
tion, serum creatinine concentration is accepted in rate of creatinine compared to that of interfering
clinical medicine as the most indicative measure of chromogens is employed to improve test performance
renal function (1, 2). (1).
The classical method for the measurement of creati- Methods employing enzymatic breakdown of creati-
nine is based on the reaction with picrate under al- nine are an alternative to the Jqffe-type creatinine
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assay. These enzyme-based methods can follow two
principally different reaction schemes. In the first
reaction scheme creatinine is deaminated by creatinine
deaminase (creatinine iminohydrolase, EC .3.5.4.21)
yielding NHJ. This compound is measured in a sub-
sequent reaction consuming NADPH or NADH
which can be monitored photometrically. In the sec-
ond reaction scheme creatinine is hydrolysed to cre-
atine by creatininase (EC 3.5.2.10). The following
breakdown of the formed creatine results eventually
in the formation of H2O2, which is used for the for-
mation of a quinone-imine dye by peroxidase.
In this study we evaluated four commercial enzymatic
creatinine assays using a DuPont dimension™ auto-
matic analyzer. Two methods are based on the cre-
atinine iminohydrolase route: Biomed Creatinine-
Duo-UV (BIO) and Raichem™ Creatinine Reagent
Enzymatic (RAI). The other two methods are based
on the creatininase route: Boehringer Mannheim Cre-
atinine PAPV(BM1) and SopaChem Creatinine (SOP).
A major problem in creatinine measurement is the
interference caused by bilirubin. This is especially true
for Jaffe methods (1). However, the Boehringer
Mannheim Creatinine PAP method also proved to be
prone to bilirubin interference (8). Adaptation of this
method by addition of K4Fe(CN)6, which increases
the specificity of the colour reaction (9), resulted in
better performance (10). The original Boehringer
Mannheim Creatinine PAP method is evaluated to-
gether with two modifications: K4Fe(CN)6 was added
with the first (BM2) or with the second reagent
(BM3).
Interference caused by bilirubin was investigated in
two ways. Firstly, solutions of creatinine in human
albumin spiked with unconjugated or conjugated (di-
tauro-) bilirubin were assayed. Secondly, icteric pa-
tient specimens were analyzed and compared to the
HPLC reference method (11).
Materials and Methods
Mater ia ls
Bilirubin, creatinine and potassium ferrocyanide (K4Fe(CN)6)
were obtained from Merck (Darmstadt, Germany); conjugated
bilirubin (sodium salt of ditauro-bilirubin) from Porphyrin
Products Inc. (Logan, UT, USA); human albumin from Behring
Werke (Marburg, Germany); Intralipid™ (a 20% fat emulsion
for intravenous injection) from Kabi Pharmacia b. v. (Woerden,
The Netherlands); TestPoint unassayed chemistry control serum
level 1 and 2 from Technicon (Tarrytown, NY, USA); Biomed
Creatinine-Duo-UV from MP Products (Soest, The Nether-
lands); Boehringer Mannheim Creatinine PAP from Boehringer
Mannheim (Mannheim, Germany); SopaChem Creatinine from
Sopar-Biochem n.v. (Nieuwegen, The Netherlands); and
Raichem™ Creatinine Reagent Enzymatic from Reagent Ap-
plications, Inc. (San Diego, CA, USA). All water used for this
study was purified by a MilliQ system (Millipore, Bedford,
MA, USA).
Modif icat ions of enzymatic creatinine tests
As the maximal test duration on ther DuPont Dimension™ is
limited to 12 minutes and the BIO method required a pre-
incubation of 3 minutes, we had to shorten its incubation time
to 9 instead of the recommended 20 minutes. For reasons of
compensation we tripled the amount of starting reagent (reagent
2). For the RAI method 1 ml reagent 2 (starter reagent) was
diluted with 2 ml of MilliQ water. This was done because the
test manual prescribed addition of 7μ1 reagent 2 and the
Dimension™ automatic analyzer for reasons of accuracy
needed to add a minimum volume of 20 μΐ. For the BM2
method 8 mg of K4Fe(CN)6 was dissolved in 20 ml of reagent
1. For the BM3 method 3 mg K4Fe(CN)6 was added to 5 ml of
reagent 2 (starter reagent). For both BM2 and BM3 the amount
of K4Fe(CN)6 represents a fair excess as this substance functions
as a catalyst and is regenerated during the final colour-forming
reaction.
Preparation of spiked albumin solutions
for interference studies
Starting from stock solutions of 47 g/1 human albumin in 50
mmol/1 Tris/HCl pH 7.4, 6 mmol/1 creatinine in 20 mmol/1 HC1
and 10 mmol/l bilirubin or ditauro-bilirubin in 100 mmol/1
NaOH, solutions were made containing 40 g/1 albumin, 100.or
300 μηιοΐ/ΐ creatinine and a bilirubin or ditauro-bilirubin con-
centration between 0 and 1000 μηιοΙ/1 (7). These solutions were
prepared and kept shielded from light. Using a solution of
haemolyzed erythrocytes in MilliQ water or Intralipid™, sim-
ilar solutions were made containing variable concentrations of,
respectively, haemoglobin or lipids. All solutions were stored
at —70 °C until further use.
Patient samples
Serum specimens used in this study were collected in various
departments in the Academic Hospital Rotterdam. All samples
were stored at —70 °C until use. Creatinine concentration was
verified by the HPLC reference method (11). Total bilirubin
concentrations was measured using a routine DuPont bilirubin
Flex™ for the Dimension™ analyzer. The distribution of bili-
rubin concentrations in the patient sera used to evaluate bili-
rubin interference is given in table 1.
Tab. 1. Frequency distribution of creatinine and total bilirubin
concentrations in the panel of patient sera used for
evaluation of bilirubin interference. The creatinine and
bilirubin concentrations mentioned are not interrelated.
Concentration range
(μπιοΙ/1)
Number of samples
Creatinine Bilirubin
< 50
50-100
101-150
151-200
201-250
251-300
301-350
351-400
401-450
C451-500
501-550
551-600
>600
18
52
8
4
6
3
__
—2
2
—1 ;
4 '*
_
6
20
24
12
7
5
6
5
3
4
4
4
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Ins t rumenta t ion
The enzymatic methods for creatinine measurement were eval-
uated on a DuPont Dimension™ ES Clinical Chemistry System
automatic analyzer. The analyzer used software version ES 1.1.
Stat is t ical analysis
Regression analysis was done using the orthogonal Deming
procedure. Intra-assay variation was calculated using series of
30 repetitive measurements of TestPoint unassayed chemistry
control serum level 1 containing 93 μπιοΐ/ΐ creatinine. Inter-
assay variation was determined using results of this same con-
trol serum measured in 12 assays performed on different days.
Results
Assay conditions provided with the reagents were
transformed for use on the DuPont Dimension™
analyzer. As kinetic measurement yielded worse re-
sults in terms of precision than end-point measure-
ment, the latter was the method of choice. For the
methods employing the enzyme creatinine iminohy-
drolase (BIO and RAI) it was necessary to optimize
the conditions. For an optimal results of the BIO
method it was essential to restrict the mixing force to
'gentle', as stronger mixing led to an unacceptably
high variation in the results. This probably resulted
from the formation of foam interfering with correct
measurement of absorbance in the case of non-deli-
cate mixing. Assay conditions of the different methods
are listed in table 2. The within-run and day-to-day
imprecision found are given in table 3.
The enzymatic creatinine methods were tested for
linearity using aqueous standards. For the BIO and
RAI method the ratio between reagent 1 and sample
was set to yield a linear result up to 1000 μπιοΐ/ΐ
creatinine. BMx (BM1, BM2 and BM3) and SOP
methods yielded linear results for creatinine concen-
trations up to 2000 μιηοΐ/ΐ. Linearity of the enzymatic
methods was also investigated using a panel of 45
serum samples with varying creatinine concentrations
up to 1000 μηαο1/1. These patient sera were not icteric,
haemolytic or lipaemic. The results of these investi-
gations are summarized in table 4 and closely agree
with the results obtained with aqueous creatinine stan-
dards.
Stability of the reagents was verified using two control
sera with creatinine concentrations of 93 and 650
μιηοΐ/ΐ and the standard provided with the SopaChem
Creatinine reagent containing 177 μπιοΐ/ΐ creatinine.
The methods were calibrated once and, subsequently,
fresh samples were repeatedly analyzed, using the
same reagents during a period of seven days. Figure
1 shows the results that were obtained using the
TestPoint level 1 control serum with 93 μιηοΐ/ΐ cre-
Tab. 2. Assay conditions of enzymatic methods for creatinine measurement
BIO BMx** RAI SOP
Sample
time of addition (s)
volume (μΐ)
wash (μΐ)
mix
Reagent 1
time of addition (s)
volume (μΐ)
wash (μΐ)
mix
Reagent 2
time of addition (s)
volume (μΐ)
wash (μΐ)
mix
0
50
20
gentle
-110
350
0
none
180
'40
20
gentle
0
10
10
moderate
-110
350
20
moderate
330
70
20
moderate
0
50
20
gentle
-110
350
0
none
300
20
20
gentle
0
15
10
moderate
-110
350
20
moderate
300
70
20
moderate
Photometer
wavelength (nin)
reference wavelength (nm)
time of measurement 1 (s)
weightfactorl*
time of measurement 2 (s)
weightfactor2*
340
405
165
0.875
720
-1000
-1.000
510
700
300
-0.813
720
1000
1.000
340
700
270
0.913
720
-1000
-1.000
540
700
270
-0.814
720
1000
1.000
* Final result = photometry 1 χ weightfactor 1
** BMx = BM1, BM2 and BM3
+ photometry 2 χ weightfactor 2
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Tab. 3. Imprecision of enzymatic methods for creatinine meas-
urement
180
BIO
BM1
BM2
BM3
RAI
SOP
Within-run
imprecision
CV (%)
7.0
1.1
2.7
0.5
0.7
0.7
Day-to-day
imprecision
CV (%)
8.9
1.7
8.1
2.1
2.8
3.5
CV = coefficient of variation
Tab. 4. Statistical data of linearity study using non-icteric sera
[test] = a x [HPLC] + b
Sy/χ
BIO
BM1
BM2
BM3
RAI
SOP
0.912
1.050
. 0.998
1.046
1.038
0.954
72.5
2.0
13.8
7.6
-2.2
38.3
0.986
0.998
0.998
0.998
0.997
0.993
29.5
10.5
11.9
10.5
15.1
21.5
Method: orthogonal Dewing procedure; range: 0—1000 μηιοΐ/ΐ;
η = 45
atinine. Similar results were obtained with the other
two materials (results not shown). The BIO, RAI and
SOP methods did not show significant change in test
outcome after a week. The BM1 method showed
results that increased constantly with time. This in-
crease was boosted by the addition of K4Fe(CN)6 to
reagent l (BM2). Surprisingly, addition of K4Fe(CN)6
to reagent 2 (BM3) resulted in a stable test outcome.
Solutions of 40 g/1 human albumin containing 100 or
300 μιηοΐ/ΐ creatinine were spiked with lipids
(Intralipid™), haemoglobin, bilirubin or ditauro-bil-
irubin in order to investigate any interference caused
by these substances. The solutions were measured
using the different enzymatic methods for creatinine
measurement. Figure 2 displays the results obtained
using the albumin solutions with 100 μιηοΐ/ΐ creati-
nine. Closely agreeing results were obtained with the
solutions with 300 μιηοΐ/ΐ (results not shown). The
result of the RAI method was diminished by the
presence of lipids, whereas the other methods were
unaffected. Haemoglobin increased the outcome of
the BIO method, whereas this slightly decreased the
result of the RAI method. The BMx and SOP methods
showed no interference with haemoglobin.
The BIO method was left almost unaffected by bili-
rubin concentrations up to 1000 μιηοΐ/ΐ for creatinine
concentrations of 100 and 300 μιηοΐ/ΐ. Ditauro-bili-
Ο 24 48 72 96 120 144 168
Time [hours]
Fig. 1. Stability of results of enzymatic methods for creatinine
measurement. The methods were calibrated once and
subsequently fresh TestPoint unassayed chemistry con-
trol serum level 1 was analyzed for a period of a week,
ο = ΒΙΟ; ο = BMI; + = BM2; p = BM3;
A = RAI; α = SOP
rubin caused an increase in test outcome that became
quite dramatic when the ditauro-bilirubin concentra-
tion was higher than 700 μιηοΐ/ΐ. The outcome ofU;he
BM1 method was strongly diminished by both bili-
rubin and ditauro-bilirubin. interference caused by
these substances was reduced by addition of
K4Fe(CN)6. Introduction of K4Fe(CN)6 to the sample
with the first reagent (BM2) yielded a slightly better
reduction of interference than introduction with the
second reagent (BM3). The RAI method displayed
excellent resistance to interference by both bilirubin
and ditauro-bilirubin at both the creatinine concen-
trations investigated. The outcome of the SOP method
showed only a little less interference than the unmo-
dified Boehringer Mannheim Creatinine PAP method
(BM1).
Creatinine was measured in a panel of 100 sera orig^·
inating from patients with total bilirubin concentra-
tions higher than 50 μιηοΐ/l. The obtained residuals,
defined as test creatinine concentration minus con-
centration obtained by HPLC, are shown in relation
to total bilirubin concentration in figure 3. For the
majority of the samples the ΒΙΟ, ΒΜ2, BM3 and RAI
methods yielded results that were not influenced or
only slightly so by the bilirubin concentration, al-
though especially the BIO and RAI methods show
some scatter for the remaining samples. However,
when residuals were plotted in relation to creatinine
concentration it was found that for the BIO method
imprecision was high and the test outcome was ele-
vated in the normal and low range (results not shown).
c The BM1 and SOP methods were strongly affected
by bilirubin. These results are in close agreement with
the interference studies using. J)ilirubin-spiked human
albumin solutions.
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Fig. 2. Interference of enzymatic methods for creatinine measurement. Solutions of human albumin containing 100 μηιοΐ/ΐ
creatinine were spiked with possibly interfering substances.
A: interference by lipids (Intralipid™); B: interference by haemoglobin; C: interference by bilirubin; D: interference by
ditauro-bilirubin
e = ΒΙΟ; ο = BMI; + = BM2; D = BM3; A = RAI; D = SOP
Discussion
In this study the evaluation of six automated methods
for the enzymatic measurement of creatinine in serum
is described. Four commercial kits were used for this
purpose. A number of practical aspects regarding the
performance of the various adaptations is given in
the tables and the figures. Below we will try to find
an explanation for some peculiarities.
For the BIO and RAI method the ratio between
reagent 1 and sample was set to yield a linear result
for creatinine concentrations up to 1000 μπιοΐ/ΐ. As
the set dynamic range of these tests correlates in-
versely with the signal amplitude at physiological cre-
atinine concentrations and, thus, to precision at this
level, the ratio is a compromise between these quan-
tities. However, the use of a larger sample volume
relatively to the BMx or SOP methods did not reduce
imprecision to a level close to that displayed by the
latter methods (see tab. 3).
The outcome of the BIO method was raised by hae-
moglobin. It has been suggested that the creatinine
concentration of haemoglobin-containing solutions is
raised because of endogenous creatinine from eryth-
rocytes that is liberated upon haemolysis (12). The
average creatinine concentration in erythrocytes is
about 160 μπιοΐ/ΐ (13). Because the maximal haemo-
globin concentration investigated corresponds
roughly to a 2% (vol/vol) erythrocyte homogenate,
this phenomenon can maximally account for an in-
crease in creatinine of about 3 μιηοΐ/ΐ. This was con-
• firmed by HPLC measurement of creatinine in these
haemolytic solutions. Therefore, the increase in the
BIO method caused by haemoglobin represents inter-
ference.
Although both the BIO and RAI methods start cre-
atinine breakdown with creatinine iminohydrolase
(EC 3.5.4.21), they display quite different degrees of
variation (see tab. 3). This might be related to the use
of different coenzymes, since the RAI method em-
ploys NADPH whereas the BIO method uses NADH.
Use of the coenzyme NADPH instead of NADH
avoids the lengthy pre-incubation otherwise required
for equilibrating interfering endogenous dehydrogen-
ase reactions (14). Therefore, the high variation in
test outcome of the BIO method might be related to
incomplete elimination of endogenous NH/ during
the pre-incubation of 180 seconds. This was supported
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 12
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Fig. 3. Residual creatinine values of icteric sera plotted against the total bilirubin concentration. Residuals are defined as test
creatinine concentration minus concentration obtained by HPLC.
a: residuals of BIO method;
b: residuals of BM1 method;
c: residuals of BM2 method;
d: residuals of BM3 method;
e: residuals of RAI method;
f: residuals of SOP method
by our findings during the optimization procedure.
However, selecting end-point instead of kinetic meas-
urement resulted in a more pronounced reduction in
variation (results not shown). As the maximal test
duration of the DuPont Dimension™ is limited to 12
minutes, it was not possible to implement a configu-
ration containing both a long pre-incubation and end-
point measurement.
Our findings for the BIO method implemented on the
DuPont Dimension™ regarding the high variation of
test outcome and the elevated results with samples
containing low creatinine concentrations, are contra-
c dieted by other studies in which these problems were
not encountered (15, 16). Although Sonntag & Schu-
mann (15) report of rare samples with low creatinine
concentrations which yielded elevated results, their
Bur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 12
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Tab. 5. Test profiles of enzymatic methods for creatinine measurement
BIO BM1 BM2 BM3 RAI SOP
Linearity up to [μηιοΐ/ΐ]
Stability
Variation*
Interference
lipids
haemoglobin
bilirubin
ditauro bilirubin
Correlation with HPLC (non-icteric)
Correlation with HPLC (icteric)
1000 2000
+
2000 2000 1000
+
2000
+
+ =
-l·-l·
increase of test outcome
constant test outcome
decrease of test outcome
high variation
low variation
conclusion is that the BIO method is suited for routine
creatinine measurement. This difference in outcome
might result from the difference in average creatinine
concentration of the samples investigated, which was
lower in the present study as compared with the others
(see tab. 1). The implementation of the enzymatic
creatinine methods on the DuPont Dimension™ was
a compromise between the recommendations of the
various creatinine kit manufacturers and the capabil-
ities of the Dimension™ analyzer. As suggested above
it may be possible that lower variation can be obtained
for the BIO method when using a test-configuration
that runs beyond the maximal test duration of the
Dimension™ analyzer.
Using the obtained results, test profiles can be com-
piled for the different methods (tab. 5) which contain
linearity, stability, variation, interference by various
substances and correlation with the HPLC reference
method. As economics can nowadays not be excluded
when selecting reagents, it is worth considering that
the relative costs per enzymatic test are 10 to 20 times
as high as for the conventional DuPont Jaffe creati-
nine Flex™ test. Taking alj analytical and clinical
aspects into account, together with the high price of
the enzymatic creatinine methods as compared with
the Jaffe reaction-based tests, the question arises
whether these enzymatic methods are satisfactory. It
is up to the reader to decide. From this study we
conclude that amongst the tested enzymatic methods
the Boehringer Mannheim Creatinine PAP method,
adapted to contain potassium hexacyanoferrate(II)
(K4Fe(CN)6) in reagent 2 (BM3), shows the best per-
formance. Further studies are needed to determine
whether the SopaChem Creatinine method, which is
based on the same reaction principle, will show a
comparable performance when adapted in a similar
manner.
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